These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24644078)

  • 1. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
    Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme.
    Angelo MG; David MP; Zima J; Baril L; Dubin G; Arellano F; Struyf F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):466-79. PubMed ID: 24644063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.
    Wu Q; Qian M; Welby S; Guignard A; Rosillon D; Gopala K; Xu Y; Liu K; He Y; Jiang N; Tan Q; Xie J; Zhu T; Wang Q; Pan Y; Zeng R; Yang J; Zhao X; Zhou M; Navarro-Torné A; Yu H; Borys D
    Hum Vaccin Immunother; 2023 Dec; 19(3):2283912. PubMed ID: 38038626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.
    Angelo MG; Taylor S; Struyf F; Tavares Da Silva F; Arellano F; David MP; Dubin G; Rosillon D; Baril L
    Expert Rev Vaccines; 2014 Nov; 13(11):1297-306. PubMed ID: 25219284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.
    Kim CJ; Song R; Chen J; Tavares Da Silva F; Gopala KB; Kim JH; Bi D; Park JS
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):837-842. PubMed ID: 28266092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events following immunization in Ontario's female school-based HPV program.
    Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
    Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years.
    Kim YJ; Kim KT; Kim JH; Cha SD; Kim JW; Bae DS; Nam JH; Ahn WS; Choi HS; Ng T; Bi D; OK JJ; Descamps D; Bock HL
    J Korean Med Sci; 2010 Aug; 25(8):1197-204. PubMed ID: 20676333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
    Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
    Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
    Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
    J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
    Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.